دورية أكاديمية
أعرض في EDS

Folate metabolism: a re-emerging therapeutic target in haematological cancers.

التفاصيل البيبلوغرافية
العنوان: Folate metabolism: a re-emerging therapeutic target in haematological cancers.
المؤلفون: Zarou MM; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.; Cancer Research UK Beatson Institute, Glasgow, UK., Vazquez A; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK. alexei.vazquez@dlr.de.; Cancer Research UK Beatson Institute, Glasgow, UK. alexei.vazquez@dlr.de., Vignir Helgason G; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK. vignir.helgason@glasgow.ac.uk.
المصدر: Leukemia [Leukemia] 2021 Jun; Vol. 35 (6), pp. 1539-1551. Date of Electronic Publication: 2021 Mar 11.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Review
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE
أسماء مطبوعة: Publication: 2000- : London : Nature Publishing Group, Specialist Journals
Original Publication: [Baltimore, Md.] : Williams & Wilkins, [c1987-
مواضيع طبية MeSH: Antineoplastic Agents/*pharmacology , Carbon/*metabolism , Folic Acid/*metabolism , Folic Acid Antagonists/*pharmacology , Hematologic Neoplasms/*drug therapy, Animals ; Hematologic Neoplasms/metabolism ; Hematologic Neoplasms/pathology ; Humans
مستخلص: Folate-mediated one carbon (1C) metabolism supports a series of processes that are essential for the cell. Through a number of interlinked reactions happening in the cytosol and mitochondria of the cell, folate metabolism contributes to de novo purine and thymidylate synthesis, to the methionine cycle and redox defence. Targeting the folate metabolism gave rise to modern chemotherapy, through the introduction of antifolates to treat paediatric leukaemia. Since then, antifolates, such as methotrexate and pralatrexate have been used to treat a series of blood cancers in clinic. However, traditional antifolates have many deleterious side effects in normal proliferating tissue, highlighting the urgent need for novel strategies to more selectively target 1C metabolism. Notably, mitochondrial 1C enzymes have been shown to be significantly upregulated in various cancers, making them attractive targets for the development of new chemotherapeutic agents. In this article, we present a detailed overview of folate-mediated 1C metabolism, its importance on cellular level and discuss how targeting folate metabolism has been exploited in blood cancers. Additionally, we explore possible therapeutic strategies that could overcome the limitations of traditional antifolates.
References: Oncologist. 2016 Dec;21(12):1471-1482. (PMID: 27496039)
Cell Metab. 2020 Apr 7;31(4):809-821.e6. (PMID: 32187526)
Leukemia. 1997 Jun;11(6):886-9. (PMID: 9177445)
Am J Med. 1980 Mar;68(3):370-6. (PMID: 6965819)
Pediatr Blood Cancer. 2013 Jul;60(7):1161-4. (PMID: 23335430)
Mol Cancer Ther. 2006 Sep;5(9):2211-7. (PMID: 16985054)
Aging (Albany NY). 2012 Jul;4(7):480-98. (PMID: 22837425)
Leukemia. 2006 Nov;20(11):1955-62. (PMID: 16990760)
Mol Cell. 2014 Jul 17;55(2):253-63. (PMID: 24882210)
Crit Rev Oncol Hematol. 2007 Jun;62(3):214-26. (PMID: 17368038)
Sci Adv. 2016 Oct 28;2(10):e1601273. (PMID: 27819051)
Nat Commun. 2014;5:3128. (PMID: 24451681)
Oncotarget. 2020 May 05;11(18):1576-1589. (PMID: 32405334)
Thorax. 1992 Aug;47(8):628-33. (PMID: 1412121)
Cancer. 1987 Dec 15;60(12):3020-4. (PMID: 3479231)
Leukemia. 2021 Feb;35(2):377-388. (PMID: 32382081)
Blood. 2008 Sep 1;112(5):2020-3. (PMID: 18544682)
Blood. 1999 Mar 1;93(5):1677-83. (PMID: 10029597)
Cancer Res. 1985 Jan;45(1):217-20. (PMID: 2578094)
Gene. 2019 Oct 20;716:144032. (PMID: 31377316)
Mol Cancer Ther. 2011 Mar;10(3):437-47. (PMID: 21262957)
Birth Defects Res A Clin Mol Teratol. 2009 Apr;85(4):274-84. (PMID: 19180567)
Nat Metab. 2019 Sep;1(9):861-867. (PMID: 31598584)
Mol Cancer. 2007 Jul 10;6:46. (PMID: 17623090)
Cancer Treat Rep. 1981;65 Suppl 4:115-21. (PMID: 7049375)
Leukemia. 2019 Oct;33(10):2403-2415. (PMID: 30940908)
J Clin Invest. 1985 Sep;76(3):907-12. (PMID: 2413074)
Leuk Res. 1991;15(12):1191-6. (PMID: 1722550)
Nature. 2018 Feb 1;554(7690):128-132. (PMID: 29364879)
Diabetes. 2015 Feb;64(2):360-9. (PMID: 25338814)
Leukemia. 2007 Apr;21(4):797-804. (PMID: 17315026)
Blood. 1953 Nov;8(11):965-99. (PMID: 13105700)
Elife. 2016 Jun 16;5:. (PMID: 27307216)
Cancer Res. 2014 Dec 15;74(24):7521-33. (PMID: 25377470)
Nature. 2014 Jun 12;510(7504):298-302. (PMID: 24805240)
Neurology. 2002 May 28;58(10):1513-20. (PMID: 12034789)
Cancer Res. 1984 Aug;44(8):3190-5. (PMID: 6204743)
J Pediatr Hematol Oncol. 2014 Oct;36(7):503-17. (PMID: 24936744)
Mol Pharmacol. 1992 Oct;42(4):687-94. (PMID: 1435744)
Eur J Cancer. 1991;27(8):1006-9. (PMID: 1832883)
Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):11404-11409. (PMID: 29073064)
Acta Oncol. 1995;34(5):611-2. (PMID: 7546826)
FEBS Lett. 2019 Jul;593(14):1863-1873. (PMID: 31127856)
Clin Chem. 2006 Apr;52(4):692-700. (PMID: 16455868)
Cell Death Dis. 2020 May 4;11(5):310. (PMID: 32366892)
J Exp Med. 2016 Jun 27;213(7):1285-306. (PMID: 27325891)
J Biol Chem. 2003 May 23;278(21):19436-41. (PMID: 12646567)
Nature. 2018 Jul;559(7715):632-636. (PMID: 29995852)
Annu Rev Nutr. 2010 Aug 21;30:57-81. (PMID: 20645850)
Cancer Metab. 2020 Sep 21;8:20. (PMID: 32974014)
Nat Rev Rheumatol. 2016 Dec;12(12):731-742. (PMID: 27784891)
Sci Rep. 2020 May 12;10(1):7838. (PMID: 32398698)
Nature. 2015 Nov 12;527(7577):186-91. (PMID: 26466563)
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6914-9. (PMID: 10359813)
Nat Rev Cancer. 2005 Jan;5(1):65-72. (PMID: 15630416)
Cancer Res. 2013 Jan 15;73(2):478-82. (PMID: 23135910)
Cancer Discov. 2021 Jun;11(6):1582-1599. (PMID: 33436370)
Nat Commun. 2018 Apr 10;9(1):1368. (PMID: 29636461)
Clin Chem. 1996 Aug;42(8 Pt 2):1322-9. (PMID: 8697606)
J Clin Oncol. 2003 Mar 15;21(6):1044-9. (PMID: 12637469)
PLoS One. 2016 Feb 26;11(2):e0150232. (PMID: 26919657)
Mol Cancer Ther. 2009 Feb;8(2):366-75. (PMID: 19174558)
Nat Cancer. 2020 Oct;1(10):998-1009. (PMID: 33479702)
Cancer Res. 1981 Nov;41(11 Pt 1):4441-6. (PMID: 6171339)
Cancer Res. 1987 Mar 1;47(5):1313-8. (PMID: 2434214)
J Biol Chem. 2002 Oct 11;277(41):38381-9. (PMID: 12161434)
Cancer. 1979 Mar;43(3):1089-94. (PMID: 284840)
Nat Commun. 2020 Jun 1;11(1):2714. (PMID: 32483148)
Jpn J Cancer Res. 1990 Nov;81(11):1162-7. (PMID: 1702414)
Eur J Cancer. 2001 Mar;37(4):492-8. (PMID: 11267859)
Nucleic Acids Res. 2013 Jan;41(Database issue):D955-61. (PMID: 23180760)
Cancer Chemother Pharmacol. 2009 Oct;64(5):993-9. (PMID: 19221750)
N Engl J Med. 1996 Oct 3;335(14):1041-8. (PMID: 8793930)
Cancer Res. 1988 Apr 15;48(8):2149-55. (PMID: 2450647)
Nat Rev Cancer. 2016 Oct;16(10):650-62. (PMID: 27634448)
Leukemia. 1995 Feb;9(2):274-6. (PMID: 7532768)
Leukemia. 2022 Feb;36(2):348-360. (PMID: 34341479)
Arch Dis Child. 1976 Dec;51(12):944-50. (PMID: 1015847)
J Clin Invest. 1983 Sep;72(3):773-8. (PMID: 6193143)
Mol Metab. 2020 Mar;33:23-37. (PMID: 31402327)
Biochem Pharmacol. 1990 Dec 15;40(12):2651-60. (PMID: 2260989)
Am J Clin Nutr. 2000 Dec;72(6):1535-41. (PMID: 11101483)
J Clin Oncol. 1999 May;17(5):1589-94. (PMID: 10334548)
N Engl J Med. 1948 Jun 3;238(23):787-93. (PMID: 18860765)
Br J Biomed Sci. 2003;60(2):117-29. (PMID: 12866924)
Ann Rheum Dis. 2003 May;62(5):423-6. (PMID: 12695153)
Cell Metab. 2016 Jun 14;23(6):1140-1153. (PMID: 27211901)
Leuk Lymphoma. 2019 Dec;60(12):3002-3010. (PMID: 31120351)
Cancer Discov. 2014 Dec;4(12):1406-17. (PMID: 25186948)
J Biol Chem. 2010 Jul 23;285(30):23056-63. (PMID: 20498374)
Clin Pharmacol Ther. 2004 Apr;75(4):274-81. (PMID: 15060506)
Cell Rep. 2014 May 22;7(4):1248-58. (PMID: 24813884)
Cell Metab. 2017 Jan 10;25(1):27-42. (PMID: 27641100)
Blood. 2007 Feb 1;109(3):896-904. (PMID: 17003366)
J Obstet Gynaecol Br Commonw. 1964 Aug;71:529-42. (PMID: 14194440)
Cell. 2018 Nov 29;175(6):1546-1560.e17. (PMID: 30500537)
Proc Natl Acad Sci U S A. 1985 Aug;82(15):4881-5. (PMID: 3860829)
Nat Metab. 2019 Mar;1:404-415. (PMID: 31058257)
Cancer Chemother Pharmacol. 1987;19(1):42-6. (PMID: 3815725)
Cancer Chemother Pharmacol. 1998;42(4):313-8. (PMID: 9744777)
Leukemia. 2006 Apr;20(4):750-4. (PMID: 16467867)
Cancer Metab. 2015 May 28;3:6. (PMID: 26023330)
معلومات مُعتمدة: 29754 United Kingdom CRUK_ Cancer Research UK; A25142 United Kingdom CRUK_ Cancer Research UK
المشرفين على المادة: 0 (Antineoplastic Agents)
0 (Folic Acid Antagonists)
7440-44-0 (Carbon)
935E97BOY8 (Folic Acid)
تواريخ الأحداث: Date Created: 20210312 Date Completed: 20210816 Latest Revision: 20240210
رمز التحديث: 20240210
مُعرف محوري في PubMed: PMC8179844
DOI: 10.1038/s41375-021-01189-2
PMID: 33707653
قاعدة البيانات: MEDLINE
الوصف
تدمد:1476-5551
DOI:10.1038/s41375-021-01189-2